Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05385705
Title A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Vall d'Hebron Institute of Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.